Neoplasms
Conditions
Keywords
DSP-0509, Toll-Like Receptor 7 (TLR-7), BLRM (Bayesian Logistic Regression Model)
Brief summary
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A). The combination arm has Dose Escalation (Part B) only.
Detailed description
The primary objective of Monotherapy Arm A is to determine the MTD or RP2D of DSP-0509 when administered as a single agent. Approximately 21 to 30 patients with advanced solid tumors will be enrolled. Several provisional dose levels of DSP-0509, with approximately 3 to 6 patients at each level may be tested in patients with advanced solid tumors. DSP-0509 will be administered as a single agent q2w beginning on Day 1. The primary objective of Combination Therapy Arm B is to determine the RP2D of DSP-0509 when administered in combination with pembrolizumab, using a BLRM approach. The combination arm will enroll approximately 21 to 30 patients with advanced solid tumors that are (a) metastatic or unresectable and recurrent, and/or refractory to available therapy, (b) a condition for which pembrolizumab is an approved treatment, and (c) in patients who have shown either primary or acquired resistance to an ICI. DSP-0509 will be administered on Day 1 and then every 2 weeks thereafter. Pembrolizumab will be initiated on Day 1. The primary objective of Combination Therapy Arm C is to determine preliminary efficacy in the form of the ORR of DSP-0509 when administered in combination with pembrolizumab to an expansion cohort of patients with HNSCC, using a Bayesian Adaptive design approach. Combination Arm C will enroll approximately 20 to 40 patients with HNSCC tumors that are (a) metastatic or unresectable, and recurrent and/or refractory to available therapy, (b) in patients who have been treated with pembrolizumab or other PD-1 or PD-L1 inhibitors in monotherapy, and (c) who have subsequently shown either primary or acquired resistance to ICIs. Dose escalation of DSP-0509 in combination with 400 mg pembrolizumab q6w will start at the same dose of DSP-0509 as the highest (not exceeding the MTD) level tested in the combination regimen with 200 mg pembrolizumab q3w. Upon completion of the DLT evaluation period for the first DSP-0509 dose level tested in combination with 400 mg pembrolizumab q6w in newly enrolled patients, if this dose level is found not to exceed the MTD, any ongoing patients receiving DSP-0509 in combination with pembrolizumab 200 mg q3w will be allowed, at the investigator's discretion, to transition to the 400 mg pembrolizumab q6w regimen, while maintaining the originally assigned DSP-0509 dose level.
Interventions
DRUGDSP-0509
Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
DRUGDSP-0509, Pembrolizumab
Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
Sponsors
Syneos Health
Sumitomo Pharma America, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must fulfill each of the following requirements: 1\. Must have a histologically or cytologically confirmed advanced solid tumor that meets the following additional specifications 1. Monotherapy Part A (Dose Escalation) advanced solid tumor that is metastatic or unresectable and recurrent and /or refractory to available therapy. 2. Combination Part B (Dose Escalation)- advanced solid tumors that are (a) metastatic or unresectable and recurrent and/or refractory to available therapy; (b) a condition for which pembrolizumab is an approved treatment: and (c) in patients who either have shown primary or acquired resistance to immune checkpoint inhibitors (ICIs) 3. Combination Arm C (Dose Expansion), Phase 2 - Advanced HNSCC tumors of the oropharynx, oral cavity, hypopharynx, larynx, lip, or sinus that are (a) metastatic or unresectable, and recurrent and/or refractory to available therapy, (b) in patients who have been treated with pembrolizumab or other PD-1 or PD-L1 inhibitors in monotherapy, and (c) who have subsequently shown primary or acquired resistance to ICIs. For enrollment in both arms: 2\. Must be ≥ 18 years of age 3\. Should have all side effects of any prior therapy or procedures for any medical condition recovered to CTCAE ≤ Grade 1 (except alopecia). 4\. Must have at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1. 5\. Must have a life expectancy ≥ 3 to 6 months. 6\. Female patients of childbearing age and women \< 12 months since the onset of menopause, except those who have been surgically sterilized (tubal ligation) or whose sexual partner(s) is surgically sterilized (vasectomy), must agree to use acceptable contraceptive methods for the duration of the study and for 9 months after the date of their last DSP-0509 infusion. If employing contraception, 2 of the following precautions must be used: birth control pill, vaginal diaphragm, intrauterine system or device, condom or vaginal spermicide. Female patients who are postmenopausal are defined as those with an absence of menses for ≥ 12 consecutive months. Male patients must be surgically sterilized (vasectomy) or their female sexual partner(s) must be surgically sterilized (tubal ligation) to avoid using contraception. If they do not meet this criterion, then male patients or must agree to use a condom as well as one of the acceptable contraceptive methods listed above with their female partner(s) who meets the criteria of either being of childbearing age or is \< 12 months since the onset of menopause. Male patients and their female partner(s) must agree to use acceptable contraception methods for the duration of time the male patient is on the study and for 9 months after the date of his last DSP 0509 infusion. 7\. Females of childbearing potential must have a negative serum pregnancy test. 8\. Must have an Eastern Cooperative Oncology Group performance status of 0 to 1. 9\. Must have adequate coagulation function at Screening as determined by: a. Prothrombin international normalized ratio \< 1.5. b. Partial thromboplastin time \< 1.5 times the upper limit of normal (ULN). 10\. Must have adequate hematologic function at Screening as determined by: a. White blood cell (WBC) count ≥ 3,000/microliter. b. Absolute neutrophil count (ANC) ≥ 1,500/microliter (patient may not use granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor to achieve these WBC and ANC levels). c. Platelet count ≥ 100 × 103/microliter. d. Hemoglobin (Hgb) ≥ 9.0 g/dL (may not transfuse or use erythropoietin to obtain this Hgb level). 11\. Must have adequate renal and hepatic function at Screening as determined by: 1. Serum creatinine \< 2.0 mg/dL or \< 1.5 times the ULN, whichever is lower. 2. Total bilirubin ≤ 1.5 mg/dL or \< 1.5 times the ULN, whichever is lower (or ≤ 2.0 mg/dL for patients with known Gilbert syndrome). 3. Aspartate aminotransferase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases). 4. Alanine aminotransferase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases). 12\. Must be able to attend study visits as required by the protocol. 13\. Prior to the first DSP-0509 infusion, the patient must be able to provide tumor tissue for baseline studies either as (a) a block of archival tissue sufficient to provide the required number of slides (b) a sufficient number of fixed, unstained slides of archival tissue or (c) consent to undergo tumor biopsy to acquire sufficient tumor tissue. (Sites need to refer to the current version of the Sample Collection & Shipment Instructions Manual to determine how many slides are required for each patient as these numbers vary based on (a) the study Arm/Part in which the patient is enrolled and (b) whether the patient consented to optional future testing). In addition to the above criteria, patients must meet the following criteria to be eligible to enroll in Combination Arm C: 14\. Have at least one accessible tumor for biopsy. This accessible lesion must be considered as non-measurable per RECIST criteria, v1.1. 15\. Be platinum refractory, PD-1 or PD-L1 exposed, and have no more than 3 lines of prior therapy for advanced/metastatic disease 16\. Have a known status of PD-L1 combined positive score (CPS) 17\. Have a known HPV status
Exclusion criteria
Patients with any of the following will be excluded from the study: For enrollment in both arms: 1. Has received prior therapy with a TLR agonist, excluding a topical TLR agonist. 2. Has received anticancer chemotherapy (including molecular-targeted drugs), radiotherapy, immunotherapy (eg, vaccines or cytokines), or investigational agents within the 3 weeks before the first dose of DSP-0509. Local palliative radiotherapy is permitted3. Receives concurrent systemic (oral or IV) steroid therapy \> 10 mg prednisone daily or its equivalent for an underlying condition. 4\. Not fully recovered from major surgery before the first dose of DSP-0509. 5\. Has central nervous system (CNS) metastases (including leptomeningeal metastases, spinal metastases) or CNS primary tumors, eg, glioblastoma. 6\. Has a history of seizures other than isolated febrile seizure in childhood; has a history of a cerebrovascular accident or transient ischemic attack less than 6 months ago. 7\. Has effusions (pleural, pericardial, or ascites) requiring drainage. 8\. Has a neurodegenerative disease, eg, motor neuron disease, Parkinson disease, Alzheimer disease, Huntington disease. 9\. Has retinal detachment, ulcerative keratitis, uveitis, Vogt-Koyanagi-Harada syndrome, choroidal neovascularization, retinopathy/retinitis, thyroid-associated orbitopathy, idiopathic orbital inflammation, diabetic retinopathy, ischemic retinopathy including glaucoma-associated retinopathy, retinal vein thrombosis, or a non-healing ocular or ophthalmic disease. 10\. Has a fever ≥ 38°C within 3 days before the first dose of study treatment. 11\. Has interstitial lung disease or active noninfectious pneumonitis. 12\. Has a history of active autoimmune or immunologic disorder requiring immunosuppression with steroids or other immunosuppressive agents (eg, azathioprine, cyclosporine A) except for patients with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave disease. Patients with controlled hyperthyroidism must be negative for thyroglobulin, thyroid peroxidase antibodies, and thyroid-stimulating immunoglobulin before study drug administration. 13\. Has a known hypersensitivity to a component of the protocol therapy, DSP-0509, or another pyrimidine. 14\. Has a history of another primary cancer within the 5 years before enrollment except for the following: non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other nonmetastatic carcinoma that has been in complete remission without treatment for more than 5 years. 15\. Has abnormal ECGs that are clinically significant, such as QT prolongation (QTc \> 480 msec). 16\. In the opinion of the treating Investigator, has any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the study results; these conditions include, but are not limited to ongoing or active infection, clinically significant non-healing or healing wounds, concurrent congestive heart failure (New York Heart Association Functional Classification Class II, III or IV), concurrent unstable angina, concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation), recent (within the prior 12 months) myocardial infarction, acute coronary syndrome within the previous 12 months, significant pulmonary disease (shortness of breath at rest or on mild exertion) for example due concurrent severe obstructive pulmonary disease, concurrent hypertension requiring more than 2 medications for adequate control, or diabetes mellitus with more than 2 episodes of ketoacidosis in the prior 12 months. 17\. Has an ejection fraction of 50% or less based on a MUGA scan or ECHO. 18\. Has the presence of a known active acute or chronic infection including human immunodeficiency virus as determined by enzyme-linked immunosorbent assay and confirmed by Western blot; and hepatitis B virus and hepatitis C virus as determined by hepatitis B surface antigen and hepatitis C serology. 19\. Has a cognitive, psychological, or psychosocial impediment that would impair the ability of the patient to receive therapy according to the protocol or adversely affect the ability of the patient to comply with the informed consent process, protocol, or protocol-required visits and procedures. 20\. Receives concurrent strong inhibitors of cytochrome P450 2C8. 21\. Receives concurrent inhibitors of organic anion transporting peptide (OATP)1B1 and OATP1B3. 22\. Is pregnant or breastfeeding. 23\. Has active neurological or inflammatory or auto immune disorders (e.g. Guillain-Barre Syndrome, Amyotrophic Lateral Sclerosis) The following exclusion applies only to enrollment in Combination arms Part B & C: 24\. Has a history of immune-related adverse events (irAEs) resulting in permanent discontinuation of ICI treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | From the time of first dose to 6 weeks after the first dose | — |
| Determination of RP2D of DSP-0509 When Given in Combination With Pembrolizumab by Assessing DLTs | 28 days | Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1). |
| Determination of the MTD of DSP-0509 When Given in Combination With Pembrolizumab by Assessing Dose-limiting Toxicities (DLTs). | 28 days | MTD of DSP-0509 in patients enrolled into the Combination Arm during the dose escalation part of the study. |
| Determination of the Recommended Phase 2 Dose (RP2D) by Assessing Dose-limiting Toxicities (DLTs) | 28 days | — |
| Preliminary Antitumor Activity of DSP-0509 in Combination With Pembrolizumab in Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) Who Have Shown Primary or Acquired Resistance to Immune Checkpoint Inhibitors (ICIs) | 4 weeks | Data to be derived from patients enrolled into the Combination Arm - Part C (Phase 2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DoR by iRECIST | 6 months | Defined as the time from first documentation of response until the time of first documentation of disease progression by iRECIST. |
| PFS by iRECIST | 12 months | Defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression by iRECIST. |
| Evaluate Single Agent DSP-0509-induced Changes in Cytokine Levels. | 8 weeks | Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1) |
| Evaluate Change in Cytokine Levels Induced by DSP-0509 in Combination With Pembrolizumab. | 8 weeks | Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1) |
| Evaluate Pharmacokinetics (PK) for Combo Agents DSP-0509 and Pembrolizumab by Assessing Plasma Concentration. | 8 weeks | Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1) |
| Progression Free Survival (PFS) by RECIST | 12 months | Defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v1.1. |
| Evaluate Pharmacokinetics (PK) for Single Agent DSP-0509 by Assessing Plasma Concentration. | 8 weeks | Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1) |
| Objective Response Rate (ORR) by RECIST | From date of first dose to 6 months post first dose | Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
| ORR by Immune RECIST (iRECIST) | From date of first dose to 6 months post first dose | Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on iRECIST. |
| Duration of Response (DoR) by RECIST | 6 months | Defined as the time from first documentation of response until the time of first documentation of disease progression by RECIST v1.1. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Identification of Potential Metabolites of DSP-0509 in Plasma and Possibly in Urine. | 8 weeks | Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1) |
| Evaluate the PFS Rate as a Potential Evaluation of Treatment Benefit of DSP-0509 Administered With Pembrolizumab | 12 months | Data to be derived from patients enrolled into Combination Arm - Part C (Phase 2) |
| Evaluate the Effect of DSP-0509 on Cardiac Parameters by Assessing Continuous 25-hour ECG Recordings. | 12 months | Data to be derived from patients enrolled into Monotherapy Arm - Part A (Phase 1) |
| Exploratory Pharmacodynamic Evaluation as Potential Efficacy-related Immune Response Biomarkers. | 12 months | — |
| Exploratory Pharmacodynamic Evaluation as Potential Biomarkers Capable of Predicting the Clinical Efficacy or Toxicity | 12 months | — |
Countries
United States
Participant flow
Recruitment details
Thirty-six patients were enrolled into the Phase 1 (dose escalation) portion of this study. The study was terminated due to Sponsor's considerations, and therefore the MTD and RP2D have not been determined. No patients were enrolled into the Phase 2 (dose expansion) portion of the study.
Pre-assignment details
Participants who progressed, died, withdrew consent to survival follow up or were lost to follow up were considered to have completed the study.
Participants by arm
| Arm | Count |
|---|---|
| Monotherapy Arm - Cohort 1 0.3mg of DSP-0509 monotherapy administered as an IV constant rate over 3 minutes weekly for 4 weeks followed by biweekly dosing. | 3 |
| Monotherapy Arm - Cohort 2 1.0mg of DSP-0509 monotherapy administered as an IV constant rate over 3 minutes weekly for 4 weeks followed by biweekly dosing. | 4 |
| Monotherapy Arm - Cohort 3 1.5mg of DSP-0509 monotherapy administered as an IV constant rate over 3 minutes weekly for 4 weeks followed by biweekly dosing. | 5 |
| Monotherapy Arm - Cohort 4 1.5mg of DSP-0509 monotherapy administered as an IV constant rate over 10 minutes every 2 weeks. | 3 |
| Monotherapy Arm - Cohort 5 2.4mg of DSP-0509 monotherapy administered as an IV constant rate over 10 minutes every 2 weeks. | 4 |
| Monotherapy Arm - Cohort 6 3.5mg of DSP-0509 monotherapy administered as an IV constant rate over 10 minutes every 2 weeks. | 7 |
| Combination Arm - Cohort 1 0.3mg DSP-0509 administered once weekly, with 200mg pembrolizumab administered once every 3 weeks | 1 |
| Combination Arm - Cohort 2 0.3mg DSP-0509 administered twice weekly, with 200mg pembrolizumab administered once every 3 weeks | 3 |
| Combination Arm - Cohort 3 1.0mg DSP-0509 administered twice weekly, with 200mg pembrolizumab administered once every 3 weeks | 3 |
| Combination Arm - Cohort 4 1.0mg DSP-0509 administered twice weekly, with 400mg pembrolizumab administered once every 6 weeks | 3 |
| Total | 36 |
Baseline characteristics
| Characteristic | Monotherapy Arm - Cohort 2 | Monotherapy Arm - Cohort 3 | Monotherapy Arm - Cohort 4 | Monotherapy Arm - Cohort 5 | Monotherapy Arm - Cohort 6 | Monotherapy Arm - Cohort 1 | Combination Arm - Cohort 1 | Combination Arm - Cohort 2 | Combination Arm - Cohort 3 | Combination Arm - Cohort 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 2 Participants | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 10 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 3 Participants | 2 Participants | 2 Participants | 6 Participants | 3 Participants | 1 Participants | 1 Participants | 3 Participants | 2 Participants | 26 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 3 Participants | 3 Participants | 3 Participants | 4 Participants | 5 Participants | 2 Participants | 1 Participants | 2 Participants | 3 Participants | 3 Participants | 29 Participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 4 Participants | 1 Participants | 0 Participants | 2 Participants | 2 Participants | 2 Participants | 16 Participants |
| Sex: Female, Male Male | 3 Participants | 4 Participants | 2 Participants | 2 Participants | 3 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 4 | 1 / 5 | 0 / 3 | 1 / 4 | 1 / 7 | 0 / 1 | 0 / 3 | 0 / 3 | 0 / 3 |
| other Total, other adverse events | 3 / 3 | 4 / 4 | 5 / 5 | 3 / 3 | 4 / 4 | 7 / 7 | 1 / 1 | 3 / 3 | 3 / 3 | 3 / 3 |
| serious Total, serious adverse events | 0 / 3 | 2 / 4 | 2 / 5 | 1 / 3 | 1 / 4 | 3 / 7 | 1 / 1 | 1 / 3 | 2 / 3 | 0 / 3 |
Outcome results
Primary
Determination of RP2D of DSP-0509 When Given in Combination With Pembrolizumab by Assessing DLTs
Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1).
Time frame: 28 days
Population: Sponsor's decision to terminate the study. Data were not collected.
Primary
Determination of the MTD of DSP-0509 When Given in Combination With Pembrolizumab by Assessing Dose-limiting Toxicities (DLTs).
MTD of DSP-0509 in patients enrolled into the Combination Arm during the dose escalation part of the study.
Time frame: 28 days
Population: Sponsor's decision to terminate the study. Data were not collected.
Primary
Determination of the Recommended Phase 2 Dose (RP2D) by Assessing Dose-limiting Toxicities (DLTs)
Time frame: 28 days
Population: Sponsor's decision to terminate the study. Data were not collected to determine the RP2D.
Primary
Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing
Time frame: From the time of first dose to 6 weeks after the first dose
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Monotherapy Arm - Cohort 1 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Monotherapy Arm - Cohort 2 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 1 Participants |
| Monotherapy Arm - Cohort 3 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 1 Participants |
| Monotherapy Arm - Cohort 4 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Monotherapy Arm - Cohort 5 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Monotherapy Arm - Cohort 6 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Combination Arm - Cohort 1 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 1 Participants |
| Combination Arm - Cohort 2 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Combination Arm - Cohort 3 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
| Combination Arm - Cohort 4 | Number of Participants With Dose-limiting Toxicities (DLTs) Within the First 6 Weeks of Dosing | 0 Participants |
Primary
Preliminary Antitumor Activity of DSP-0509 in Combination With Pembrolizumab in Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) Who Have Shown Primary or Acquired Resistance to Immune Checkpoint Inhibitors (ICIs)
Data to be derived from patients enrolled into the Combination Arm - Part C (Phase 2)
Time frame: 4 weeks
Population: Sponsor's decision to terminate study. No patients were enrolled into phase 2 of the study.
Secondary
DoR by iRECIST
Defined as the time from first documentation of response until the time of first documentation of disease progression by iRECIST.
Time frame: 6 months
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Duration of Response (DoR) by RECIST
Defined as the time from first documentation of response until the time of first documentation of disease progression by RECIST v1.1.
Time frame: 6 months
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Evaluate Change in Cytokine Levels Induced by DSP-0509 in Combination With Pembrolizumab.
Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1)
Time frame: 8 weeks
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Evaluate Pharmacokinetics (PK) for Combo Agents DSP-0509 and Pembrolizumab by Assessing Plasma Concentration.
Data to be derived from patients enrolled into the Combination Arm - Part B (Phase 1)
Time frame: 8 weeks
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Evaluate Pharmacokinetics (PK) for Single Agent DSP-0509 by Assessing Plasma Concentration.
Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1)
Time frame: 8 weeks
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Evaluate Single Agent DSP-0509-induced Changes in Cytokine Levels.
Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1)
Time frame: 8 weeks
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Objective Response Rate (ORR) by RECIST
Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: From date of first dose to 6 months post first dose
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
ORR by Immune RECIST (iRECIST)
Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on iRECIST.
Time frame: From date of first dose to 6 months post first dose
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
PFS by iRECIST
Defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression by iRECIST.
Time frame: 12 months
Population: Sponsor's decision to terminate study. Data were not collected.
Secondary
Progression Free Survival (PFS) by RECIST
Defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v1.1.
Time frame: 12 months
Population: Sponsor's decision to terminate study. Data were not collected.
Other Pre-specified
Evaluate the Effect of DSP-0509 on Cardiac Parameters by Assessing Continuous 25-hour ECG Recordings.
Data to be derived from patients enrolled into Monotherapy Arm - Part A (Phase 1)
Time frame: 12 months
Population: Sponsor's decision to terminate study. Data were not collected.
Other Pre-specified
Evaluate the PFS Rate as a Potential Evaluation of Treatment Benefit of DSP-0509 Administered With Pembrolizumab
Data to be derived from patients enrolled into Combination Arm - Part C (Phase 2)
Time frame: 12 months
Population: Sponsor's decision to terminate study. No patients were enrolled into Phase 2 of the study.
Other Pre-specified
Exploratory Pharmacodynamic Evaluation as Potential Biomarkers Capable of Predicting the Clinical Efficacy or Toxicity
Time frame: 12 months
Population: Sponsor's decision to terminate study. Data were not collected.
Other Pre-specified
Exploratory Pharmacodynamic Evaluation as Potential Efficacy-related Immune Response Biomarkers.
Time frame: 12 months
Population: Sponsor's decision to terminate study. Data were not collected.
Other Pre-specified
Identification of Potential Metabolites of DSP-0509 in Plasma and Possibly in Urine.
Data to be derived from patients enrolled into the Monotherapy Arm - Part A (Phase 1)
Time frame: 8 weeks
Population: Sponsor's decision to terminate study. Data were not collected.